Journal of Pharmacology and Experimental Therapeutics 2013-09-01

Physical presence of nor-binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on κ-opioid receptors.

Kshitij A Patkar, Jinhua Wu, Michelle L Ganno, Harminder D Singh, Nicolette C Ross, Khampaseuth Rasakham, Lawrence Toll, Jay P McLaughlin

Index: J. Pharmacol. Exp. Ther. 346(3) , 545-54, (2013)

Full Text: HTML

Abstract

In the mouse 55°C warm-water tail-withdrawal assay, a single administration of nor-binaltorphimine (nor-BNI; 10 mg/kg i.p.) antagonized κ-opioid receptor (KOR) agonist-induced antinociception up to 14 days, whereas naloxone (10 mg/kg i.p.)-mediated antagonism lasted less than 1 day. In saturation binding experiments, mouse brain membranes isolated and washed 1 or 7 (but not 14) days after nor-BNI administration demonstrated a significant time-dependent decrease in maximal KOR agonist [(3)H]U69,593 binding. To determine whether brain concentrations of nor-BNI were sufficient to explain the antagonism of KOR-mediated antinociception, mouse blood and perfused brain were harvested at time points ranging from 30 minutes to 21 days after a single administration and analyzed for the presence of nor-BNI using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). Nor-BNI was detected in the perfused brain homogenate up to 21 days after administration (30 nmol i.c.v. or 10 mg/kg i.p.). Subsequent experiments in which nor-BNI was administered at doses estimated from the amounts detected in the brain homogenates isolated from pretreated mice over time demonstrated significant antagonism of U50,488 antinociception in a manner consistent with the magnitude of observed KOR antagonism. The dose (1.4 nmol) approximating the lowest amount of nor-BNI detected in brain on day 14 did not antagonize U50,488-induced antinociception, consistent with the absence of U50,488 antagonism observed in vivo at this time point after pretreatment. Overall, the physical presence of nor-BNI in the mouse brain paralleled its in vivo pharmacological profile, suggesting physicochemical and pharmacokinetic properties of nor-BNI may contribute to the prolonged KOR antagonism.


Related Compounds

Related Articles:

Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

2014-07-01

[J. Pharmacol. Exp. Ther. 350(1) , 69-78, (2014)]

Desensitization of functional µ-opioid receptors increases agonist off-rate.

2014-07-01

[Mol. Pharmacol. 86(1) , 52-61, (2014)]

Treatment of alcohol dependence: recent progress and reduction of consumption.

2014-12-01

[Minerva Med. 105(6) , 447-66, (2014)]

Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.

2014-05-14

[JAMA 311(18) , 1889-900, (2014)]

Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response.

2013-05-01

[Addict. Behav. 38(5) , 2119-27, (2013)]

More Articles...